Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Type 2
Interventions: Exenatide (AC2993), Insulin glargine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 21
States / cities: San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 85
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Meal-Tagging App and Web-based Portal:, Fitness Tracker; Other · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 25 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina

Conditions: Growth Hormone Deficiency With Pituitary Anomalies
Interventions: Macimorelin, Insulin; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Torrance, California • Austin, Texas • Houston, Texas + 1 more

Conditions: Type 1 Diabetes
Interventions: Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5; Device
Lead sponsor: Marc Breton; Other
Eligibility: 24 Months to 71 Months
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: Multiple daily ijnection using Insulin Degludec and Insulin Aspart; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin Lispro Protamine Suspension, Insulin Levemir; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Idaho Falls, Idaho • Springfield, Illinois • Topeka, Kansas + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Canakinumab, Placebo, Metformin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more

Conditions: Bioequivalence in Healthy Subjects
Interventions: Insulin Lispro; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions: Synthetic Human Parathyroid Hormone 1-34 pump; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 7 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Control Group; Device
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 13 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 1 more

Conditions: IGF1 Deficiency
Interventions: Increlex®; Drug
Lead sponsor: Esteve Pharmaceuticals, S.A.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 7
States / cities: Orange, California • Miami, Florida • Cincinnati, Ohio + 2 more

Conditions: Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Interventions: rhIGF-1 (mecasermin) for a period of 86 weeks; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 3 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Insulin glargine, Insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 52
States / cities: Little Rock, Arkansas • Anaheim, California • Concord, California + 44 more

Conditions: Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions: Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 35 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 14
States / cities: Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 11 more

Conditions: Diabetes Mellitus
Interventions: insulin glargine, insulin glulisine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Gan & Lee Insulin Lispro Injection, Humalog; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 58
States / cities: Anaheim, California • Fresno, California • Los Angeles, California + 52 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20); Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Bionic Pancreas, Usual Care; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions: FlexTouch®, FlexPen®; Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 65
States / cities: Burlingame, California • Concord, California • Encino, California + 59 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 74
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more

Search by objective public record fields.

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

Insulin Pump to Multiple Daily Injection Transition Clinical Trial

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

A Study of t:Slim X2 With Control-IQ Technology

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

Triple Therapy in T1DM

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period